Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin

J. E. Taylor, R. A. MacTier, I. S. Henderson, J. J. Belch, W. K. Stewart

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)

    Abstract

    OBJECTIVE: To determine the effect of subcutaneous erythropoietin treatment on dialysis efficiency in continuous ambulatory peritoneal dialysis (CAPD) patients. DESIGN: Dialysis efficiency, platelet and white cell aggregation, and red cell deformability were measured monthly for six months in nine anaemic CAPD patients treated with erythropoietin, and on a single occasion in seven control CAPD patients with intrinsically high haemoglobin concentrations. SETTING: Renal dialysis unit. PATIENTS: Nine patients stable on CAPD for a minimum of six months and with haemoglobin concentrations less than 8.5 g/dl were treated with erythropoietin. Seven CAPD patients matched for age and renal function, with haemoglobins greater than 9.0 g/dl served as controls. RESULTS: Daily peritoneal clearances and net ultrafiltration volumes were unchanged when haematocrit increased from 25.0 +/- 2.2% to 36.5 +/- 3.5%. Spontaneous whole blood platelet aggregation was significantly increased from week twelve (pre-treatment aggregation 46 +/- 23%; 12 weeks: 67 +/- 19%, p less than 0.05; 16 weeks: 64 +/- 19%, p less than 0.01; 20 weeks: 71 +/- 16%, p less than 0.01; 24 weeks: 73 +/- 10%, p less than 0.01). CONCLUSIONS: The increase in haematocrit and platelet aggregation associated with erythropoietin treatment did not affect peritoneal clearances or ultrafiltration capacity.
    Original languageEnglish
    Pages (from-to)221-226
    Number of pages6
    JournalPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
    Volume12
    Issue number2
    Publication statusPublished - 1992

    Fingerprint

    Dive into the research topics of 'Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin'. Together they form a unique fingerprint.

    Cite this